IW-3300 rectal foam + Placebo

Phase 2Terminated
0 watching 0 views this week Active
44
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Interstitial Cystitis

Conditions

Interstitial Cystitis, Bladder Pain Syndrome

Trial Timeline

Mar 28, 2023 → Feb 6, 2025

About IW-3300 rectal foam + Placebo

IW-3300 rectal foam + Placebo is a phase 2 stage product being developed by Ironwood Pharmaceuticals for Interstitial Cystitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05740007. Target conditions include Interstitial Cystitis, Bladder Pain Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05740007Phase 2Terminated

Competing Products

20 competing products in Interstitial Cystitis

See all competitors
ProductCompanyStageHype Score
Ferumoxytol + GadobutrolLipella PharmaceuticalsPhase 1
25
LP-08 80mg + Normal saline + LP-08 20mgLipella PharmaceuticalsPhase 2
44
tacrolimusAstellas PharmaPre-clinical
23
ASP3652 + PlaceboAstellas PharmaPhase 2
52
Mirabegron + PlaceboAstellas PharmaPhase 3
77
TacrolimusAstellas PharmaPhase 2/3
65
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Placebo + JNJ-42160443Johnson & JohnsonPhase 2
52
Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved
85
BOTOX + Placebo for BOTOXAbbViePhase 2
52
NS-863 Low Dose + NS-863 High DoseNippon ShinyakuPhase 2
52
INS316 solution for inhalation + hypertonic saline 3% sodium chloride solutionMerckPhase 2
52
Abituzumab 1500 mg + Abituzumab 500 mg + PlaceboMerckPhase 2
52
MK-2225 + PlaceboMerckPhase 1
33
Certican® + Neoral + Myfortic + Simulect® + CorticosteroidsNovartisPhase 3
77
Pirfenidone + PlaceboRochePhase 2
52
PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685PfizerPhase 2
51
Tanezumab + Tanezumab + Tanezumab + TanezumabPfizerPhase 2
51
ERB-041PfizerPre-clinical
22
PF-04383119 + PlaceboPfizerPhase 2
51